|
[1]
|
LiVolsi VA, Baloch ZW. Follicular neoplasms of the thyroid:view, biases, and experiences[J]. Adv Anat Pathol, 2004, 11:279-287. doi: 10.1097/01.pap.0000138143.34505.02 |
|
[2]
|
Williams D. Cancer after nuclear fallout:lessons from the Chernobyl accident[J]. Nat Rev Cancer, 2002, 2:543-549. doi: 10.1038/nrc845 |
|
[3]
|
DeLellis RA, LIoyd RV, Heitz PU, et al. World Health Organization classification of tumours:pathology and genetics of tumours of endocrine organs[M]. Lyon:IARC press, 2004. |
|
[4]
|
Vitagliano D, Portella G, Troncone G, et al. Thyroid targeting of the N-ras (Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas[J]. Oncogene, 2006, 25:5467-5474. doi: 10.1038/sj.onc.1209527 |
|
[5]
|
Suzuki H, Willingham MC, Cheng SY. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma:a mouse model of thyroid carcinogenesis[J]. Thyroid, 2002, 12:963-969. doi: 10.1089/105072502320908295 |
|
[6]
|
Lu C, Zhu X, Willingham MC, et al. Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma[J]. Oncogene, 2012, 31:2007-2016. doi: 10.1038/onc.2011.390 |
|
[7]
|
Reddi HV, McIver B, Grebe SK, et al.The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis[J]. Endocrinology, 2007, 148:932-935. doi: 10.1210/en.2006-0926 |
|
[8]
|
Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors:evidence for distinct molecular pathways in thyroid follicular carcinoma[J]. J Clin Endocrinol Metab, 2003, 88:2318-2326. doi: 10.1210/jc.2002-021907 |
|
[9]
|
Bhaijee F, Nikiforov YE. Molecular analysis of thyroid tumors[J]. Endocr Pathol, 2011, 22:126-133. doi: 10.1007/s12022-011-9170-y |
|
[10]
|
Kalvakolanu DV. The GRIMs:a new interface between cell death regulation and interferon/retinoid induced growth suppression[J].Cytokine Growth Factor Rev, 2004, 15:169-194. doi: 10.1016/j.cytogfr.2004.01.002 |
|
[11]
|
Nagy R, Ganapathi S, Comeras I, et al. Frequency of germline PTEN mutations in differentiated thyroid cancer[J].Thyroid, 2011, 21:505-510. doi: 10.1089/thy.2010.0365 |
|
[12]
|
Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors[J]. Cancer, 2008, 113:2440-2447. doi: 10.1002/cncr.23869 |
|
[13]
|
Vella V, Puppin C, Damante G, et al. DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells[J]. Int J Cancer, 2009, 124:2539-2548. doi: 10.1002/ijc.24221 |
|
[14]
|
Yeager N, Klein-Szanto A, Kimura S, et al. Pten loss in the mouse thyroid causes goiter and follicular adenomas:insights into thyroid function and cowden disease pathogenesis[J]. Cancer Res, 2007, 67:959-966. doi: 10.1158/0008-5472.CAN-06-3524 |
|
[15]
|
Antico-Arciuch VG, Dima M, Liao XH, et al.Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females[J]. Oncogene, 2010, 29:5678-5686. doi: 10.1038/onc.2010.308 |
|
[16]
|
Miller KA, Yeager N, Baker K, et al. Oncogenic K-ras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo[J]. Cancer Res, 2009, 69:3689-3694. doi: 10.1158/0008-5472.CAN-09-0024 |
|
[17]
|
Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers[J]. J Clin Endocrinol Metab, 2008, 93:3106-3116. doi: 10.1210/jc.2008-0273 |
|
[18]
|
Saji M, Narahara K, McCarty SK, et al. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer[J]. Oncogene, 2011, 30:4307-4315. doi: 10.1038/onc.2011.136 |
|
[19]
|
Williams ED. Guest editorial:two proposals regarding the terminology of thyroid tumors[J].Int J Surg Pathol, 2000, 8:181-183. doi: 10.1177/106689690000800304 |
|
[20]
|
Liu Z, Zhou G, Nakamura M, et al. Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential:a morphological, immunohistochemical, and molecular appraisal[J]. Cancer Sci, 2011, 102:288-294. doi: 10.1111/j.1349-7006.2010.01769.x |
|
[21]
|
Smith RA, Salajegheh A, Weinstein S, et al, Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant[J].Hum Pathol, 2011, 42:500-506. doi: 10.1016/j.humpath.2009.09.023 |
|
[22]
|
Rivera M, Ricarte-Filho J, Knauf J, et al, Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns[J]. Mod Pathol, 2010, 23:1191-1200. doi: 10.1038/modpathol.2010.112 |
|
[23]
|
Pusztaszeri M, Pache JC, Karenovics W, et al, A non-invasive encapsulated macrofollicular variant of papillary thyroid carcinoma presenting with gross lymph node metastasis:a case report and literature review[J]. Thyroid, 2013, 23:1178-1179. doi: 10.1089/thy.2013.0032 |
|
[24]
|
Rivera M, Ricarte-Filho J, Patel S, et al. Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis):a clinicopathologic and molecular study[J]. Hum Pathol, 2010, 41:172-180. doi: 10.1016/j.humpath.2009.08.011 |
|
[25]
|
Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma:the turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach[J]. Am J Surg Pathol, 2007, 31:1256-1264. doi: 10.1097/PAS.0b013e3180309e6a |
|
[26]
|
van Heerden JA, Hay ID, Goellner JR, et al. Follicular thyroid carcinoma with capsular invasion alone:a nonthreatening malignancy[J]. Surgery, 1992, 112:1130-1136; discussion 1136-1138. |
|
[27]
|
Lang W, Choritz H, Hundeshagen H. Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings[J]. Am J Surg Pathol, 1986, 10:246-255. doi: 10.1097/00000478-198604000-00003 |
|
[28]
|
Magro G, Cataldo I, Amico P, et al. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target[J].Thyroid, 2011, 21:267-277. doi: 10.1089/thy.2010.0173 |
|
[29]
|
Abulkheir IL, Mohammad DB.Value of immunohistochemical expression of p27 and galectin-3 in differentiation between follicular adenoma and follicular carcinoma[J]. Appl Immunohistochem Mol Morphol, 2012, 20:131-140. doi: 10.1097/PAI.0b013e318228de00 |
|
[30]
|
Heikkilä A, Hagström J, Mäenpää H, et al. Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome[J].Thyroid, 2013, 23:456-465. doi: 10.1089/thy.2012.0363 |
|
[31]
|
Sugino K, Kameyama K, Ito K, et al. Outcomes and prognostic factors of 251 patients with minimally invasive follicular thyroid carcinoma[J].Thyroid, 2012, 22:798-804. doi: 10.1089/thy.2012.0051 |
|
[32]
|
Kangelaris GT, Orloff LA. Prognostic factors for minimally invasive follicular thyroid carcinoma[J]. Laryngoscope, 2011, 121:S130. doi: 10.1002/lary.22007 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
